Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 6901-6910 Newer>

The Motley Fool April 20, 2005 Jack Uldrich	FEI Goes Smaller to Get Bigger The nanotech equipment manufacturer unveils its most advanced microscope. this announcement definitely gives FEI a leg up on its main nanotech-equipment competitor -- Veeco.
The Motley Fool April 20, 2005 David Meier	WaMu: It Pays to Wait Earn 5% while waiting for Washington Mutual's stock price to appreciate.
The Motley Fool April 20, 2005 Rich Smith	Crunching the Data Crunchers Have the info-theft hackers given us any bargains in the stock market? Here is a bargain evaluation for four data companies recently affected by hackers.
The Motley Fool April 20, 2005 Stephen D. Simpson	A Healing Look at Bard Medical device maker C.R. Bard shows that boring can be beautiful so long as boring pays the bills. Investors, take note.
The Motley Fool April 20, 2005 Stephen D. Simpson	No Wooden Nickels for Inco Strong nickel prices lead to big earnings growth for the world's second-largest producer.
The Motley Fool April 20, 2005 Mike Cianciolo	At Least It's a Profit Ford's still profitable, but earnings are off by a third.
The Motley Fool April 20, 2005 Stephen D. Simpson	St. Jude's Healthy Heartbeat Medical device maker St. Jude continues to be boosted by ICD market share gains, and new businesses are coming on line, as well.
The Motley Fool April 20, 2005 Stephen D. Simpson	Wolverine Claws Its Way to Growth Outdoor and lifestyle brands are driving growth at a company traditionally known for work boots. Investors, take note.
The Motley Fool April 20, 2005 Rich Duprey	Waiting for WiMax The Wi-Fi successor has been called "broadband on steroids." It has been a long time coming, but Intel's release of its WiMax "Rosedale" chip on Monday heralds its arrival. What will it mean for investors?
The Motley Fool April 20, 2005 Stephen D. Simpson	Wyeth Looking Healthier Improving sales are helping this troubled drugmaker recover a little faster. Big pharma investors might see Wyeth as one of the more interesting growth and turnaround candidates in the industry.
<Older 6901-6910 Newer> Return to current articles.